Anbio Biotechnology (NNNN) Return on equity 2022–2025
Anbio Biotechnology (NNNN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
21.2%FY2025 · since FY2022: 79.8% → 21.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 21.2% | +7.4 pp |
| FY2024 | 13.8% | -1.4 pp |
| FY2023 | 15.2% | -64.6 pp |
| FY2022 | 79.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice